FoxO3 Transcription Factor and Sirt6 Deacetylase Regulate Low Density Lipoprotein (LDL)-cholesterol Homeostasis via Control of the Proprotein Convertase Subtilisin/Kexin Type 9 (Pcsk9) Gene Expression

Hepatic SREBP-2 and cholesterol biosynthesis are regulated by FoxO3 and Sirt6

(2013) Rongya Tao et al.   JOURNAL OF LIPID RESEARCH

Delineation of molecular pathways that regulate hepatic PCSK9 and LDL receptor expression during fasting in normolipidemic hamsters

(2012) Minhao Wu et al.   ATHEROSCLEROSIS

The novel function of HINFP as a co-activator in sterol-regulated transcription ofPCSK9in HepG2 cells

(2012) Hai Li et al.   BIOCHEMICAL JOURNAL

Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice

(2012) Maxime Denis et al.   CIRCULATION

Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia

(2012) Frederick Raal et al.   CIRCULATION

LDL cholesterol targets – how low to go?

(2012) Richard Bulbulia et al.   CURRENT OPINION IN LIPIDOLOGY

Proprotein convertase subtilisin/kexin type 9 inhibition

(2012) David A. Marais et al.   CURRENT OPINION IN LIPIDOLOGY

Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients

(2012) David Sullivan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Peroxisome Proliferator-activated Receptor γ Activation by Ligands and Dephosphorylation Induces Proprotein Convertase Subtilisin Kexin Type 9 and Low Density Lipoprotein Receptor Expression

(2012) Yajun Duan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice

(2012) Ding Ai et al.   JOURNAL OF CLINICAL INVESTIGATION

The PCSK9 decade

(2012) Gilles Lambert et al.   JOURNAL OF LIPID RESEARCH

Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels

(2012) Clapton S. Dias et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

(2012) Michael J Koren et al.   LANCET

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study

(2012) Robert P Giugliano et al.   LANCET

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

(2012) Evan A Stein et al.   LANCET

Regulation of cholesterol homeostasis

(2012) Mariëtte Y.M. van der Wulp et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

The Deacetylase Sirt6 Activates the Acetyltransferase GCN5 and Suppresses Hepatic Gluconeogenesis

(2012) John E. Dominy et al.   MOLECULAR CELL

The sirtuin SIRT6 regulates lifespan in male mice

(2012) Yariv Kanfi et al.   NATURE

Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

(2012) Evan A. Stein et al.   NEW ENGLAND JOURNAL OF MEDICINE

Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia

(2012) Eli M. Roth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cell cycle-dependent deacetylation of telomeric histone H3 lysine K56 by human SIRT6

(2011) Eriko Michishita et al.   CELL CYCLE

The sirtuin SIRT6 deacetylates H3 K56Ac in vivo to promote genomic stability

(2011) Bo Yang et al.   CELL CYCLE

Hepatic Suppression ofFoxo1andFoxo3Causes Hypoglycemia and Hyperlipidemia in Mice

(2011) Kebin Zhang et al.   ENDOCRINOLOGY

Hepatic FoxOs Regulate Lipid Metabolism via Modulation of Expression of the Nicotinamide Phosphoribosyltransferase Gene

(2011) Rongya Tao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells

(2011) Aiqin Cao et al.   JOURNAL OF LIPID RESEARCH

Replication of an association of variation in the FOXO3A gene with human longevity using both case-control and longitudinal data

(2010) Mette Soerensen et al.   AGING CELL

Circulating Proprotein Convertase Subtilisin Kexin Type 9 Has a Diurnal Rhythm Synchronous With Cholesterol Synthesis and Is Reduced by Fasting in Humans

(2010) Lena Persson et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Hepatic-Specific Disruption of SIRT6 in Mice Results in Fatty Liver Formation Due to Enhanced Glycolysis and Triglyceride Synthesis

(2010) Hyun-Seok Kim et al.   Cell Metabolism

Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans

(2010) Jeffrey D. Browning et al.   JOURNAL OF LIPID RESEARCH

Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters

(2010) Bin Dong et al.   JOURNAL OF LIPID RESEARCH

SIRT6 protects against pathological damage caused by diet-induced obesity

(2009) Yariv Kanfi et al.   AGING CELL

SIRT6 Links Histone H3 Lysine 9 Deacetylation to NF-κB-Dependent Gene Expression and Organismal Life Span

(2009) Tiara L.A. Kawahara et al.   CELL

Hepatocyte Nuclear Factor 1α Plays a Critical Role inPCSK9Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine

(2009) Hai Li et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Association ofFOXO3Avariation with human longevity confirmed in German centenarians

(2009) Friederike Flachsbart et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Association of the FOXO3A Locus with Extreme Longevity in a Southern Italian Centenarian Study

(2009) Chiara Viviani Anselmi et al.   REJUVENATION RESEARCH

Berberine decreases PCSK9 expression in HepG2 cells

(2008) Jamie Cameron et al.   ATHEROSCLEROSIS

Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo

(2008) Robert J. Schmidt et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Inactivation of Hepatic Foxo1 by Insulin Signaling Is Required for Adaptive Nutrient Homeostasis and Endocrine Growth Regulation

(2008) Xiaocheng C. Dong et al.   Cell Metabolism

Importance of Proprotein Convertase Subtilisin/Kexin Type 9 in the Hormonal and Dietary Regulation of Rat Liver Low-Density Lipoprotein Receptors

(2008) Lena Persson et al.   ENDOCRINOLOGY

Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes

(2008) Cédric Langhi et al.   FEBS LETTERS

Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9

(2008) Sanae Kourimate et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice

(2008) Yi Luo et al.   JOURNAL OF LIPID RESEARCH

SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin

(2008) Eriko Michishita et al.   NATURE

FOXO-binding partners: it takes two to tango

(2008) K E van der Vos et al.   ONCOGENE

FOXO3A genotype is strongly associated with human longevity

(2008) B. J. Willcox et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Diabetes alters LDL receptor and PCSK9 expression in rat liver

(2007) Melissa Niesen et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS